Portage Biotech Highlights First Patient Dosed in IMP-MEL Study of PORT-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer (NSCLC)

Portage Biotech Inc., announced that the first patient has been dosed in the Oxford-led IMP-MEL study, a Phase I/II, open-label, dose-escalation and randomized expansion clinical trial assessing the safety, tolerability and efficacy of PORT-2, a liposome formulation of the invariant natural killer T-cell agonist IMM60 developed for the treatment of solid tumors.